Sorrento Hits Snag On $200M Scilex Stock Sale In Ch. 11
Bankrupt drug developer Sorrento Therapeutics told a Texas judge Tuesday that its planned $200 million sale of its equity in nondebtor subsidiary Scilex Holding Co. had hit a snag, forcing the...To view the full article, register now.
Already a subscriber? Click here to view full article